Strategic Investment Boosts CHA Biotech’s Plans for Digital Healthcare
CHA Biotech said it got 10 billion won in funding from LG CNS to help with the growth of digital healthcare. The investment creates a long-term strategic partnership that will focus on advanced healthcare platforms and technology-driven medical services.
CHA Biotech got the money by giving out new shares to a third party. The company is the parent company of CHA Bio Group and runs a number of healthcare subsidiaries.
Source: The Korea Times
Partnership Includes Important Healthcare and AI Partners
Several CHA Bio Group companies will be directly involved in the collaboration. These include CHA Healthcare and CHA AI Healthcare. Kakao Healthcare will also help speed up the development of the platform and the integration of healthcare data by sharing their knowledge.
At the CHA Bio Complex in Pangyo, executives from both companies signed the agreement in front of witnesses. Cha Won-tae, the Vice Chairman of CHA Bio Group, and Hyun Shin-gyoon, the CEO of LG CNS, were there.
Initial Focus Targets Cloud Infrastructure and Unified Medical Data Platforms
The short-term phase focuses on moving CHA Bio Group systems to cloud-based infrastructure environments. The companies will also build a smart big data platform that links hospitals, labs, and pharmaceutical service providers.
The goal of this integration is to make clinical workflows better, make diagnoses faster, and make medical data available in real time across all healthcare institutions. The platform will bring together all operational information to help medical operations make decisions based on data.
Recommended Article: mWell Grows Telehealth Access in Remote Philippine Communities
Using AI to Make the Process of Making Treatments More Efficient
CHA Biotech and LG CNS want to use AI to make drug production more modern. Upgrades will be made to manufacturing facilities to improve quality control, automate processes, and make treatment development pipelines more efficient.
The companies think that AI can make production more consistent and make it easier to scale up advanced therapeutic products. The goal of these changes is to make the group more competitive in the global biotechnology and healthcare markets.
Long-Term Vision Centers on Connected AI-Driven Healthcare Services
The partnership will make money off of an AI-based connected healthcare platform that will help patients in many different medical settings. The system will automatically look for health risks by looking at hospital records and data from wearable devices.
When something goes wrong, the platform will put patients in touch with doctors or emergency services right away. This method aims to raise the number of early interventions and lower the number of avoidable complications in high-risk patient groups.
Advanced Language Models Power Healthcare Analytics Platform
LG CNS has made specialized large language models that the healthcare platform will use to understand medical data. It will also use the EXAONE AI model made by LG AI Research for genetic analysis.
These models will work together to analyze large clinical and genomic datasets and give personalized healthcare recommendations and predictions. During the development of the platform, the companies stressed the importance of strict data security rules and following the law.
Global Expansion Planned Through CHA International Hospital Network
CHA Bio Group wants to use its hospital networks in four countries to roll out the digital healthcare platform around the world. Singapore, Australia, Japan, and the United States are some of the target markets. CHA already runs medical facilities in these countries.
The goal of the expansion plan is to make digital healthcare services more standardized while still meeting the needs of different regions’ laws and clinics. Both companies think that growth in other countries will greatly boost long-term platform adoption and business viability.
Executives Emphasize Digital Transformation as Competitive Necessity
Cha Won-tae, the Vice Chairman, said that digital transformation and artificial intelligence are very important for the future of healthcare. He stressed that new technologies are still necessary for long-term growth in the quickly changing global medical industries.
LG CNS said again that it would help modernize healthcare by providing advanced software infrastructure and AI services. The partnership shows how biotechnology, digital platforms, and data-driven patient care systems are coming together more and more.
